HSP90 Heat-Shock Proteins, antagonists & inhibitors

Name
HSP90 Heat-Shock Proteins, antagonists & inhibitors
Accession Number
DBCAT001671
Description

Not Available

Drugs
DrugDrug Description
TanespimycinInvestigated for use/treatment in leukemia (myeloid) and solid tumors.
RetaspimycinInvestigated for use/treatment in gastric cancer, lung cancer, and multiple myeloma.
OnalespibInvestigated for use/treatment in cancer/tumors (unspecified).
AUY922AUY922 has been used in trials studying the treatment of Lymphoma, Breast Cancer, Metastatic Disease, Advanced Solid Tumors, and Hematologic Neoplasms, among others.
GanetespibGanetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome.
BIIB021BIIB021 has been investigated for the treatment of Tumors and Lymphoma.
XL-888XL888 has been used in trials studying the treatment of Cancer and Melanoma.
IPI-493IPI-493 has been used in trials studying the treatment of Advanced Malignancies.
SNX-2112SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor.
Drugs & Drug Targets
DrugTargetType
TanespimycinHeat shock protein HSP 90-alphatarget
TanespimycinHeat shock protein HSP 90-betatarget
TanespimycinSerum albumincarrier